Trial Profile
A Randomized, Double-blind, Placebo-controlled, Loaded Phase III Clinical Trial on the Efficacy and Safety of Mepozumab for Injection in the Treatment of Post-COVID-19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Meplazumab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Pacific Meinuoke Biopharmaceutical
- 21 Feb 2024 Status changed from recruiting to completed.
- 17 Apr 2023 New trial record